A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Bowlus, CL; Galambos, MR; Aspinall, RJ; Hirschfield, GM; Jones, DEJ; Dorffel, Y; Gordon, SC; Harrison, SA; Kremer, AE; Mayo, MJ; Thuluvath, PJ; Levy, C; Swain, MG; Neff, GW; Sheridan, DA; Stanca, CM; Berg, CP; Goel, A; Shiffman, ML; Vierling, JM; Boudes, P; Steinberg, A; Choi, YJ; McWherter, CA

Bowlus, CL (通讯作者)，Univ Calif Davis, One Shields Ave, Davis, CA 95616 USA.

JOURNAL OF HEPATOLOGY, 2022; 77 (2): 353

Abstract

Background & Aims: We examined the efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, in adu......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索